Athersys Company Profile (NASDAQ:ATHX)

About Athersys (NASDAQ:ATHX)

Athersys logoAthersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ATHX
  • CUSIP: N/A
  • Web:
  • Market Cap: $233.52 million
  • Outstanding Shares: 113,911,000
Average Prices:
  • 50 Day Moving Avg: $2.17
  • 200 Day Moving Avg: $1.69
  • 52 Week Range: $1.02 - $2.63
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.83
  • P/E Growth: -0.34
Sales & Book Value:
  • Annual Revenue: $3.43 million
  • Price / Sales: 68.08
  • Book Value: $0.23 per share
  • Price / Book: 8.91
  • EBITDA: ($27,300,000.00)
  • Net Margins: -729.07%
  • Return on Equity: -121.47%
  • Return on Assets: -88.83%
  • Current Ratio: 4.50%
  • Quick Ratio: 4.50%
  • Average Volume: 1.13 million shs.
  • Beta: -0.15
  • Short Ratio: 11.19

Frequently Asked Questions for Athersys (NASDAQ:ATHX)

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) posted its earnings results on Wednesday, August, 9th. The company reported ($0.06) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.06). The firm had revenue of $0.67 million for the quarter, compared to analysts' expectations of $0.96 million. Athersys had a negative return on equity of 121.47% and a negative net margin of 729.07%. The company's quarterly revenue was up 12.4% on a year-over-year basis. During the same period last year, the firm earned ($0.08) EPS. View Athersys' Earnings History.

When will Athersys make its next earnings announcement?

Athersys is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Athersys.

Where is Athersys' stock going? Where will Athersys' stock price be in 2017?

3 analysts have issued 1-year target prices for Athersys' shares. Their forecasts range from $7.00 to $12.00. On average, they expect Athersys' stock price to reach $9.50 in the next year. View Analyst Ratings for Athersys.

What are analysts saying about Athersys stock?

Here are some recent quotes from research analysts about Athersys stock:

  • 1. According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (10/10/2017)
  • 2. Maxim Group analysts commented, "A negative blogger blasted Athersys Multistem with Zombie" like properties as a therapeutic that just won’t die. The article (in our opinion) picks and chooses elements of the Athersys story which when taken out of context paint a confusing picture." (10/5/2017)

Who are some of Athersys' key competitors?

Who are Athersys' key executives?

Athersys' management team includes the folowing people:

  • Gil Van Bokkelen Ph.D., Chairman of the Board, Chief Executive Officer
  • William Lehmann Jr, President, Chief Operating Officer
  • John J. Harrington Ph.D., Executive Vice President, Chief Scientific Officer, Director
  • Robert J. Deans Ph.D., Executive Vice President - Regenerative Medicine
  • Laura K. Campbell CPA, Vice President - Finance
  • Lee E. Babiss Ph.D., Lead Independent Director
  • Ismail Kola, Independent Director
  • Lorin Jeffry Randall, Independent Director
  • Jack L. Wyszomierski, Independent Director

How do I buy Athersys stock?

Shares of Athersys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Athersys' stock price today?

One share of Athersys stock can currently be purchased for approximately $2.05.

MarketBeat Community Rating for Athersys (NASDAQ ATHX)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  222
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Athersys (NASDAQ:ATHX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.50 (363.41% upside)
Consensus Price Target History for Athersys (NASDAQ:ATHX)
Price Target History for Athersys (NASDAQ:ATHX)
Analysts' Ratings History for Athersys (NASDAQ:ATHX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/5/2017Maxim GroupSet Price TargetBuy$12.00N/AView Rating Details
3/28/2017William BlairReiterated RatingOutperformHighView Rating Details
2/7/2017Needham & Company LLCInitiated CoverageBuy$7.00N/AView Rating Details
1/10/2016WBB SecuritiesReiterated RatingBuy$9.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Athersys (NASDAQ:ATHX)
Earnings by Quarter for Athersys (NASDAQ:ATHX)
Earnings History by Quarter for Athersys (NASDAQ ATHX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.06)N/AView Earnings Details
8/9/2017Q2 2017($0.06)($0.06)$0.96 million$0.67 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.07)($0.06)$0.45 million$1.50 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.08)($0.10)$0.45 million$0.98 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.10)($0.07)$0.60 million$0.31 millionViewListenView Earnings Details
8/9/2016Q216($0.10)($0.08)$0.32 million$0.60 millionViewN/AView Earnings Details
5/5/2016Q1($0.08)$0.06$1.85 million$15.45 millionViewN/AView Earnings Details
3/10/2016Q4($0.09)$0.04$3.72 million$10.61 millionViewListenView Earnings Details
11/5/2015Q315($0.07)($0.08)$1.75 million$0.40 millionViewListenView Earnings Details
8/6/2015Q2($0.08)$0.02$2.66 million$0.22 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.16)$2.01 million$0.73 millionViewListenView Earnings Details
3/12/2015Q414($0.09)($0.08)$0.50 million$0.24 millionViewN/AView Earnings Details
11/10/2014Q314($0.09)($0.11)$0.54 million$0.29 millionViewN/AView Earnings Details
8/11/2014Q214($0.09)($0.06)$0.70 million$0.40 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.09)$0.66 million$0.71 millionViewN/AView Earnings Details
3/13/2014Q413($0.11)($0.15)$1.81 million$0.92 millionViewN/AView Earnings Details
11/14/2013Q3($0.12)($0.10)$0.49 million$0.62 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.12)($0.11)$390.00 million$0.57 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.11)($0.18)$1.58 million$0.33 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.12)$2.51 million$1.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Athersys (NASDAQ:ATHX)
2017 EPS Consensus Estimate: ($0.27)
2018 EPS Consensus Estimate: ($0.42)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.07)($0.07)($0.07)
Q2 20172($0.07)($0.06)($0.07)
Q3 20172($0.07)($0.06)($0.07)
Q4 20172($0.08)($0.06)($0.07)
Q1 20181($0.09)($0.09)($0.09)
Q2 20181($0.10)($0.10)($0.10)
Q3 20181($0.11)($0.11)($0.11)
Q4 20181($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)


Dividend History for Athersys (NASDAQ:ATHX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Athersys (NASDAQ:ATHX)
Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 19.11%
Insider Trades by Quarter for Athersys (NASDAQ:ATHX)
Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)
Insider Trades by Quarter for Athersys (NASDAQ:ATHX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/19/2017William Lehmann JrInsiderSell15,000$2.38$35,700.00View SEC Filing  
9/18/2017John J HarringtonEVPSell15,000$2.17$32,550.00View SEC Filing  
6/16/2017John J HarringtonEVPSell36,000$1.45$52,200.00View SEC Filing  
2/1/2017Ismail KolaDirectorBuy15,000$1.01$15,150.00View SEC Filing  
2/1/2017Laura K CampbellInsiderBuy20,000$1.01$20,200.00View SEC Filing  
12/19/2016William Lehmann JrInsiderSell3,000$1.60$4,800.00View SEC Filing  
12/16/2016John J HarringtonEVPSell15,000$1.60$24,000.00View SEC Filing  
9/19/2016William Lehmann JrInsiderSell3,000$1.96$5,880.00View SEC Filing  
9/16/2016John J HarringtonEVPSell15,000$1.96$29,400.00View SEC Filing  
6/21/2016William Lehmann JrCOOSell25,000$2.17$54,250.00View SEC Filing  
3/21/2016William Lehmann JrCOOSell25,000$2.41$60,250.00View SEC Filing  
12/21/2015William Lehmann, Jr.COOSell25,000$1.03$25,750.00View SEC Filing  
9/21/2015Bokkelen Gil VanCEOSell9,500$1.36$12,920.00View SEC Filing  
9/21/2015John J. HarringtonEVPSell8,150$1.36$11,084.00View SEC Filing  
9/21/2015William Lehmann, Jr.COOSell25,000$1.36$34,000.00View SEC Filing  
6/22/2015William Lehmann JrCOOSell25,000$1.21$30,250.00View SEC Filing  
6/19/2015John J HarringtonInsiderSell8,150$1.23$10,024.50View SEC Filing  
6/19/2015Robert J DeansEVPSell5,080$1.23$6,248.40View SEC Filing  
6/9/2015Kenneth H TraubDirectorBuy30,000$1.27$38,100.00View SEC Filing  
3/20/2015William Lehmann JrCOOSell25,000$3.14$78,500.00View SEC Filing  
3/19/2015Bokkelen Gil VanCEOSell9,500$3.10$29,450.00View SEC Filing  
3/19/2015Robert J DeansEVPSell5,080$3.10$15,748.00View SEC Filing  
12/19/2014Bokkelen Gil VanCEOSell9,500$1.29$12,255.00View SEC Filing  
12/19/2014Robert J DeansEVPSell5,080$1.28$6,502.40View SEC Filing  
12/19/2014William Lehmann JrCOOSell30,000$1.29$38,700.00View SEC Filing  
9/24/2014Kenneth H TraubDirectorBuy30,000$1.39$41,700.00View SEC Filing  
9/22/2014William Lehmann JrCOOSell30,000$1.40$42,000.00View SEC Filing  
9/19/2014Bokkelen Gil VanCEOSell9,500$1.41$13,395.00View SEC Filing  
9/19/2014John J HarringtonInsiderSell8,150$1.41$11,491.50View SEC Filing  
9/19/2014Robert J DeansEVPSell5,080$1.41$7,162.80View SEC Filing  
8/18/2014Lorin RandallDirectorSell15,000$1.54$23,100.00View SEC Filing  
6/20/2014William Lehmann JrCOOSell12,000$1.58$18,960.00View SEC Filing  
6/19/2014Bokkelen Gil VanCEOSell9,500$1.63$15,485.00View SEC Filing  
6/19/2014John J HarringtonInsiderSell8,150$1.63$13,284.50View SEC Filing  
6/19/2014Robert J DeansEVPSell5,080$1.63$8,280.40View SEC Filing  
6/19/2014William Lehmann JrCOOSell13,000$1.62$21,060.00View SEC Filing  
3/20/2014William Lehmann JrCOOSell25,000$3.62$90,500.00View SEC Filing  
3/18/2014Bokkelen Gil VanCEOSell9,500$3.54$33,630.00View SEC Filing  
3/18/2014John J HarringtonInsiderSell8,150$3.54$28,851.00View SEC Filing  
3/18/2014Robert J DeansEVPSell5,080$3.54$17,983.20View SEC Filing  
12/20/2013William Lehmann JrCOOSell25,000$2.13$53,250.00View SEC Filing  
12/11/2013Kenneth H TraubDirectorBuy20,000$1.94$38,800.00View SEC Filing  
9/20/2013John J HarringtonInsiderSell30,000$1.82$54,600.00View SEC Filing  
9/20/2013William Lehmann JrCOOSell12,000$1.83$21,960.00View SEC Filing  
11/28/2012Laura K CampbellVPBuy10,000$1.01$10,100.00View SEC Filing  
11/15/2012Robert J DeansEVPBuy3,500$0.99$3,465.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Athersys (NASDAQ:ATHX)
Latest Headlines for Athersys (NASDAQ:ATHX)
DateHeadline logoBears On Parade - Regardless, Athersys Is Developing Key Relationships For A Successful Future - October 14 at 2:43 AM logoFeatured Company News - Athersys Signs Agreement with Nikon CeLL Innovation for Commercial Manufacturing of MultiStem in Japan - October 13 at 4:39 PM logoAthersys Partners Up: Can Nikon CeLL Get MultiStem On Track? - Seeking Alpha - October 13 at 2:58 AM logoAthersys (ATHX) in Focus: Stock Moves 7.2% Higher - Nasdaq - October 13 at 2:58 AM logoAthersys (ATHX) in Focus: Stock Moves 7.2% Higher - October 12 at 4:57 PM logoAthersys Hikes on MultiStem Hookup with Japanese Firm - October 11 at 5:41 PM logoAthersys (ATHX) Reports Collaboration Agreement with Nikon Cell Innovation Co. on MultiStem Commercial Manufacturing in Japan - October 11 at 5:41 PM logoAthersys and Nikon CeLL Innovation to Collaborate on MultiStem® Commercial Manufacturing in Japan - October 11 at 5:41 PM logoAthersys, Inc. (ATHX) Rating Lowered to Hold at Zacks Investment Research - October 10 at 5:46 PM logoMid-Day Market Update: Crude Oil Up 2.7%; MannKind Shares Spike Higher - October 10 at 5:25 PM logoAthersys to Host Third Quarter Financial Results Call - October 9 at 11:35 AM logoAthersys (ATHX) & Its Rivals Head to Head Survey - October 8 at 9:00 AM logoWilliam Blair Weighs in on Athersys, Inc.'s Q1 2018 Earnings (ATHX) - October 6 at 11:04 AM logo3 Things In Biotech You Should Learn Today: October 6, 2017 - October 6 at 9:07 AM logoMaxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price Target - October 5 at 9:30 PM logoMaxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price Target - October 5 at 9:30 PM logoAthersys (ATHX) Announces RMAT Designation From FDA - - October 5 at 7:01 PM logoAthersys: Cash Concerns Cast A Long Shadow - Seeking Alpha - September 28 at 4:33 PM logoInsider Selling: Athersys, Inc. (ATHX) EVP Sells 15,000 Shares of Stock - September 19 at 8:32 PM logoAthersys, Inc. (ATHX) Insider William Lehmann, Jr. Sells 15,000 Shares - September 19 at 8:32 PM logoRegulatory Alignment Reinforces Bullish Case For Athersys - Seeking Alpha - September 19 at 4:09 PM logoAthersys Multistem Partner Healios KK Delays Implementation Of Critical Phase III TREASURE Trial - Seeking Alpha - September 11 at 4:12 PM logoAthersys (ATHX) in Focus: Stock Moves 10.22% Higher - Nasdaq - September 8 at 2:12 AM logoAthersys, Inc. (ATHX) Given Buy Rating at Maxim Group - September 4 at 2:32 PM logoAthersys, Inc. to Post Q4 2017 Earnings of ($0.08) Per Share, William Blair Forecasts (NASDAQ:ATHX) - August 14 at 6:42 AM logoAthersys, Inc. (ATHX) Posts Earnings Results, Meets Estimates - August 10 at 3:42 PM logoEdited Transcript of ATHX earnings conference call or presentation 9-Aug-17 8:30pm GMT - August 10 at 3:35 PM logoAthersys Reports Second Quarter 2017 Results - GlobeNewswire (press release) - August 9 at 4:20 PM logoFeatured Company News – Athersys Reported Alignment of Key Regulators for Pivotal Registration Study in Ischemic Stroke - August 9 at 4:20 PM logoInvestor Network: Athersys, Inc. to Host Earnings Call - August 9 at 4:19 PM logoAthersys Reports Second Quarter 2017 Results - August 9 at 4:19 PM logoAthersys Reports Alignment of Key Regulators for Pivotal Registration Study in Stroke - August 7 at 4:56 PM logoMaxim Group Analysts Give Athersys, Inc. (ATHX) a $9.00 Price Target - August 7 at 1:08 PM logoAthersys, Inc. (ATHX) to Release Earnings on Wednesday - August 2 at 7:18 AM logoAthersys's Cardiovascular Health Program Is Ambitious and Well-Calculated - Seeking Alpha - July 28 at 10:22 PM logoAthersys to Host Second Quarter Financial Results Call - GlobeNewswire (press release) - July 10 at 4:10 PM logoAthersys to Host Second Quarter Financial Results Call - July 10 at 4:10 PM logo Athersys, Inc. (NASDAQ:ATHX) Receives Consensus Recommendation of "Strong Buy" from Brokerages - July 10 at 2:30 PM logoETFs with exposure to Athersys, Inc. : July 7, 2017 - July 8 at 7:02 AM logoAthersys And Aurinia Target Human And Animal Health - Seeking Alpha - June 27 at 3:50 PM logoWhy Athersys, Inc. (ATHX) Could Be Positioned for a Surge - Nasdaq - June 9 at 2:28 AM logoUpcoming Short- And Long-Term Catalysts For Athersys - Seeking Alpha - May 31 at 3:41 PM logoAthersys Poised For Lucrative Stem Cell Stroke Partnership This Year - May 16 at 12:30 PM logoAthersys beats by $0.01, beats on revenue - May 11 at 9:11 PM logoAthersys: Initiating Coverage With Buy Rating And Price Target Of $8 - April 19 at 4:00 PM logoHere's What Might Be Pushing Up Shares of Athersys, Inc. Today - March 31 at 3:49 PM logoAthersys (ATHX) Stock Rallies as William Blair Initiates Coverage - March 29 at 8:53 PM logoAthersys (ATHX) Says Two Publications Highlight MultiStem for Treating Ischemic Stroke - March 20 at 8:53 AM logoTwo New Publications Highlight the Potential for MultiStem® Treatment of Ischemic Stroke - March 20 at 8:53 AM logo6:31 am Athersys announces that clinical investigators have published results from Athersys' Phase 2 trial of MultiStem cell therapy for treating ischemic stroke patients in the peer-reviewed journal The Lancet Neurology - March 20 at 8:53 AM



Athersys (ATHX) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.